Literature DB >> 19666429

[Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?].

Teoman Kiliç1, Ertan Ural, Gökhan Oner, Tayfun Sahin, Metehan Kiliç, Sadan Yavuz, Muhip Kanko, Göksel Kahraman, Ulaş Bildirici, Kamil Turan Berki, Dilek Ural.   

Abstract

OBJECTIVE: The aim of this study to investigate prognostic efficacy of high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS) and to identify the most valuable cut-off value of hs-CRP for determining long term prognosis.
METHODS: A total of 240 ACS patients presenting within 6 h after the onset of chest pain were included to the study. Admission levels of hs-CRP were analyzed. Patients were followed for 1 year. Primary end-point of the study was new coronary event (NCE), defined as the combination of cardiac death, nonfatal myocardial infarction and recurrent rest angina. Risk factors for NCE were determined by logistic regression analysis. ROC-curve analysis was used to identify cut-off values of the risk factors. The prognostic efficacy of the cut-off value of hs-CRP was compared to other values determined from other studies. Kaplan Meier and log rank tests were used in survival analyses. Factors determining event-free survival were investigated by Cox regression analysis.
RESULTS: During the follow-up period, 65 NCEs occurred. In multivariate analysis, hs-CRP was strongly associated with the occurrence of NCE (OR=4.79, 95% CI=2.10-10.44, p<0.001). Cut-off value of hs-CRP for NCE was 1.1 mg/dl (AUC=0.68, 95% CI=0.62-0.74, p<0.001). Compared to other values of different studies, hs-CRP>1.1 mg/dl had the optimal positive and negative predictive values. In the Cox regression analysis, hs-CRP was emerged as the most important parameter for determining event-free survival (RR=3.44, 95% CI=1.91-6.21, p<0.001).
CONCLUSION: Admission levels of hs-CRP were emerged as the most important parameter for prognosis and the cut-off value of hs-CRP for predicting NCE was found as 1.1 mg/dl in this cohort of the study population. Further studies are required to confirm the most risky cut off value of hs-CRP for predicting long term prognosis among ACS patients and in general population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666429

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  5 in total

1.  Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.

Authors:  M Karakose; K Demircan; E Tutal; T Demirci; M S Arslan; M Sahin; H T Celik; F Kazanci; J Karakaya; E Cakal; T Delibasi
Journal:  J Endocrinol Invest       Date:  2016-05-04       Impact factor: 4.256

2.  The Correlation between High-Sensitivity C-Reactive Protein (hsCRP) Serum Levels and Severity of Coronary Atherosclerosis.

Authors:  Mohammad Assadpour Piranfar
Journal:  Int Cardiovasc Res J       Date:  2014-01-01

3.  Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile.

Authors:  Magdalena Krintus; Marek Kozinski; Anna Stefanska; Marcin Sawicki; Karolina Obonska; Tomasz Fabiszak; Jacek Kubica; Grazyna Sypniewska
Journal:  Mediators Inflamm       Date:  2012-10-16       Impact factor: 4.711

4.  Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients.

Authors:  Evrim Cakir; Mustafa Ozbek; Mustafa Sahin; Erman Cakal; Askin Gungunes; Zeynep Ginis; Taner Demirci; Tuncay Delibasi
Journal:  J Ovarian Res       Date:  2012-12-18       Impact factor: 4.234

5.  Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.

Authors:  Basak Karbek; Mustafa Ozbek; Melia Karakose; Oya Topaloglu; Nujen Colak Bozkurt; Evrim Cakır; Muyesser Sayki Aslan; Tuncay Delibasi
Journal:  J Ovarian Res       Date:  2014-03-14       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.